Adenovirus-mediated transfer of tris-shRNAs induced apoptosis of nasopharyngeal carcinoma cell in vitro and in vivo

Cancer Letters

Volumn 309, Issue 2, 2011, Pages 162-169

  Han, Ji Bo ^a   Tao, Ze Zhang ^a   Chen, Shi Ming ^a   Kong, Yong Gang ^a   Xiao, Bo Kui ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Adenoviral vectors; Multi genes silencing; NPC; RNAi

Indexed keywords

ADENOVIRUS VECTOR; PROTEIN BCL XL; SHORT HAIRPIN RNA; TELOMERASE REVERSE TRANSCRIPTASE; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; BCL-X PROTEIN; BLOTTING, WESTERN; CELL LINE, TUMOR; FLOW CYTOMETRY; GENETIC VECTORS; HUMANS; INDOLES; MICE; MICE, INBRED BALB C; MICE, NUDE; NASOPHARYNGEAL NEOPLASMS; POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING; TELOMERASE; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE;

EID: 79960843844     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.05.028     Document Type: Article

References (28)

1. Hannon G.J. RNA interference. Nature 2002, 418:244-251.
2. Sharma Anurag, Tandon Manish, et al. Adenoviral vector-based strategies for cancer therapy. Curr. Drug Ther. 2009, 4:117-138.
3. Iorns E., Lord C.J., Turner N., Ashworth A. Utilizing RNA interference to enhance cancer drug discovery. Nat. Rev. Drug. Discovery 2007, 6:556-568.
4. Ashihara E., Kawata E., Maekawa T. Future prospect of RNA interference for cancer therapies. Curr. Drug Targets 2010, 11:345-360.
5. Gartel A.L., Kandel E.S. RNA interference in cancer. Biomol. Eng. 2006, 23:17-34.
6. Phalon Connor, Rao Donald D., Nemunaitis John Potential use of RNA interference in cancer therapy. Expert Rev. Mol. Med. 2010, 12.
7. Croce Carlo M. Oncogenes and cancer. N. Engl. J. Med. 2008, 358:502-511.
8. ter Brake O., 't Hooft K., et al. Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition. Mol. Ther. 2008, 16:557-564.
9. Henry S.D., van der Wegen, et al. Simultaneous targeting of HCV replication and viral binding with a single lentiviral vector containing multiple RNA interference expression cassettes. Mol. Ther. 2006, 14:485-493.
10. Wang Y., Tao Z.Z., et al. TERT and Bcl-xl expression in laryngeal squamous carcinoma. Cancer Biol. Ther. 2008, 7:896-901.
11. St George J.A. Gene therapy progress and prospects: adenoviral vectors. Gene Ther. 2003, 10:135-1141.
12. Brunetti-Pierri N., Ng P. Progress and prospects: gene therapy for genetic diseases with helper-dependent adenoviral vectors. Gene Ther. 2008, 15:553-560.
13. Blagbrough Ian S., Zara Chiara Animal models for target diseases in gene therapy-using DNA and siRNA delivery strategies. Pharm. Res. 2009, 26:1-14.
14. DeGroot L.J., Zhang R. Viral mediated gene therapy for the management of metastatic thyroid carcinoma. Curr. Drug Targets: Immune, Endocr. Metab. Disord. 2004, 4:235-244.
15. Gondi Christopher S., Rao Jasti S. Concepts in in vivo siRNA delivery for cancer therapy. J. Cell. Physiol. 2009, 220:285-291.
16. Weiler J., Hunziker J., Hall J. Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease?. Gene Ther. 2006, 13:496-502.
17. Abdolhamid Angaji S., Hedayati Sara Sadate, et al. Application of RNA interference in treating human diseases. J. Genet. 2010, 89:527-535.
18. Zhang H., Wang H.B., et al. Enhanced therapeutic efficacy by simultaneously targeting two genetic defects in tumors. Mol. Ther. 2009, 17:57-64.
19. Song Y., Dong M.M., Yang H.F. Effects of RNA interference targeting four different genes on the growth and proliferation of nasopharyngeal carcinoma CNE-2Z cells. Cancer Gene Ther. 2011, 18:297-304.
20. Bild A.H., et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006, 439:353-357.
21. Phalon Connor, Rao Donald D., Nemunaitis John Potential use of RNA interference in cancer therapy. Expert Rev. Mol. Med. 2010, 12:1-15.
22. Yoo Peter S., Mulkeen Abby L., Cha Charles H. Post-transcriptional regulation of vascular endothelial growth factor: implications for tumor angiogenesis. World J. Gastroenterol. 2006, 12:4932-4937.
23. Liua J.P., Chen S.M., et al. Regulation of telomerase activity by apparently opposing elements. Ageing Res. Rev. 2010, 9:245-256.
24. Horikawa Izumi, Carl Barrett J. Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms. Carcinogenesis 2003, 24:1167-1176.
25. Del Bufalo D., Rizzo A., et al. Involvement of hTERT in apoptosis induced by interference with Bcl-2 expression and function. Cell Death Differ. 2005, 12:1429-1438.
26. Lessene Guillaume, Czabotar Peter E., Colman Peter M. BCL-2 family antagonists for cancer therapy. Nat. Rev 2008, 7:989-996.
27. Sharma Anurag, Tandon Manish, et al. Adenoviral vector-based strategies for cancer therapy. Curr. Drug Ther. 2009, 4:117-138.
28. Pan J.J., Zhang S.W., et al. Effect of recombinant adenovirus-p53 combined with radio-therapy on long-term prognosis of advanced nasopharyngeal carcinoma. J. Clin. Oncol. 2009, 27:799-803.